-
A Breakthrough in Lung Cancer Treatment: FDA Approves Rybrevant + Lazertinib Combination
NYSE: $JNJ A New Frontier in Targeted Therapy In a significant development for oncology, Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved Rybrevant (amivantamab-vmjw) in combination with lazertinib. This treatment is specifically indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung…
-
New Data on Lilly’s Investigational Treatment Olomorasib at ESMO 2026 Show Durable First-Line Activity in KRAS G12C-Mutant Non-Small Cell Lung Cancer
NYSE: $LLY INDIANAPOLIS, Oct. 25, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced new first-line data on olomorasib, its investigational, next-generation KRAS G12C inhibitor, at the 2026 European Society for Medical Oncology… Source: Read More
-
A New Milestone in Oncology: FDA Grants Accelerated Approval to Hyrnuo (sevabertinib)
OTCMKTS: $BAYRY A Breakthrough for NSCLC Patients The landscape of cancer treatment continues to evolve with the recent news that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Hyrnuo (sevabertinib). This development marks a significant shift for patients diagnosed with non-small cell lung cancer (NSCLC). What is Hyrnuo? Hyrnuo represents the…
-
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for Ibtrozi (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
NYSE: $NUVB NEW YORK, Sept. 16, 2026 /PRNewswire/ — Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved… Source: Read More
-
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
NYSE: $MRK Tokyo – (September 25, 2026) – The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada… Source: Read More
-
Zipalertinib Shows Promise in Non-Small Cell Lung Cancer Clinical Trial
NASDAQ: $CGEM A Significant Milestone for Targeted Therapy Recent clinical data has brought a wave of optimism for patients battling non-small cell lung cancer (NSCLC). According to recent reports, the combination of zipalertinib and standard chemotherapy has successfully met its primary endpoint in a planned interim analysis, demonstrating a statistically significant improvement in progression-free survival…